Clinical Trials
Monday, May 21st, 2012
The Lancet: May 2, 2012. Previous studies have suggested that any benefits of folic acid-based therapy to lower serum homocysteine in prevention of cardiovascular events might be offset by concomitant use of antiplatelet therapy. We aimed to establish whether there is an interaction between antiplatelet therapy and the effects of folic acid-based homocysteine-lowering therapy on major […]
Clinical Trials
Sunday, May 13th, 2012
The Lancet Neurology, Early Online Publication, 8 May 2012. In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess […]
Clinical Trials
Sunday, May 13th, 2012
Sciencemag.org: Science 4 May 2012: From the Nuremberg Code onward, the core mission of human subjects research ethics has been to protect study participants from infringements motivated by a zeal for medical progress. However, with individuals, clinicians, and policymakers increasingly dependent on scientific information for decision-making and with vast social resources invested in developing and utilizing the […]
Clinical Trials
Sunday, May 13th, 2012
Iom.edu: May 4, 2012. Participant in the activities of the Institute of Medicine Forum on Drug Discovery, Development, and Translation. This commentary was developed following the Forum’s November 2011 workshop to envision a transformed U.S. clinical trials enterprise. Note: The views expressed in commentaries are those of the authors and not necessarily of the authors’ organizations or […]
Clinical Trials
Sunday, May 13th, 2012
Survey results show that the recruitment of Latino subjects requires specialized tactics. Appliedclinicaltrialsonline.com: Publish Date: May 1, 2012 By: Carmen R. GonzalezWhen it comes to attracting Latino subjects into clinical studies, there are unique requirements that differentiate this population from other audiences to warrant a tailored approach. Recently, Healthcare Communications Group undertook a survey of actively participating subjects of […]
Clinical Trials
Sunday, May 13th, 2012
Onlinelibrary.wiley.com: Volume 47, Issue 3pt2, pages 1363–1386, June 2012. We found 19 articles meeting inclusion criteria. Of these, 14 were published from 2007 to 2010. Articles described some measures of community participation in research with great variability. Although CBPR trials examined a wide range of behavioral and clinical outcomes, such trials had very high success rates in recruiting and […]
Clinical Trials
Saturday, May 5th, 2012
Worldwide 56,000-patient registry to assess safety and outcomes associated with antithrombotic treatments RIDGEFIELD, Conn., May 3, 2012 /PRNewswire. Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of the GLORIA™-AF Registry Program, the largest prospective observational study in non-valvular atrial fibrillation (NVAF) planned at this time. With a goal of enrolling 56,000 patients, the registry aims to understand […]
Clinical Trials
Saturday, May 5th, 2012
Nejm.org: May 2,2012 METHODS We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for […]
Clinical Trials
Saturday, May 5th, 2012
Ahajournals.org: April 19,2012. Background and Purpose—To date, the association between depressive symptoms and the risk of cardiovascular diseases remains controversial. We investigated prospectively, within the same population, the time course of the association between baseline depressive symptoms and first stroke or coronary heart disease event. Methods—In the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study, […]
Clinical Trials
Saturday, May 5th, 2012
Results published in Stroke showed lower absolute ICH mortality rates for PRADAXA compared to warfarin RIDGEFIELD, Conn., April 18, 2012 /PRNewswire. A new retrospective sub-analysis of the 18,113 patient RE-LY® trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared with warfarin. […]
